Table 1.
Improvement and stabilisation of lung functions after tocilizumab therapy (in per cent of predicted value)
| Pulmonary function tests | |||||||
| February 2012 | May 2013 | December 2014 | April 2016 | July 2018 | October 2022 | ||
| Patient 1 | |||||||
| TLC | 52 | Start tocilizumab | 73 | 81 | 79 | 96 | 94 |
| FEV1 | 60 | 69 | 74 | 79 | 85 | 80 | |
| DLCO | 38 | 65 | 61 | 75 | Technical problem | 74 | |
| October 2011 | April 2012 | October 2012 | May 2013 | December 2015 | August 2019 | November 2021 | ||
| Patient 2 | ||||||||
| TLC | 121 | 87 | 86 | Start tocilizumab | 104 | 99 | 108 | 96 |
| FEV1 | 99 | 48 | 55 | 56 | 82 | 89 | 94 | |
| DLCO | 97 | 50 | 51 | 87 | 78 | 77 | 74 |
DLCO, diffusing capacity of the lungs for carbon monoxide; FEV1, forced expiratory volume in 1 s; TLC, total lung capacity.